Vanda Pharmaceuticals Advances Dry Eye Treatment with VSJ-110 Study
Vanda Pharmaceuticals ((VNDA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Vanda Pharmaceuticals is conducting an eight-week clinical study titled An Eight-Week, Double-Masked, Randomized, Placebo-Controlled, Phase 2, Evaluation of the Safety and Efficacy of VSJ-110 Ophthalmic Solution in the Treatment of Dry Eye. The study aims to assess the safety and efficacy of the VSJ-110 solution compared to a placebo in treating dry eye, a condition affecting millions worldwide.
Intervention/Treatment: The study tests VSJ-110, an experimental ophthalmic solution, against a placebo. The goal is to determine its effectiveness in alleviating symptoms of dry eye.
Study Design: This is a randomized, double-masked, placebo-controlled trial with a parallel intervention model. Participants, care providers, investigators, and outcomes assessors are all masked to ensure unbiased results. The primary purpose is treatment-focused.
Study Timeline: The study began on September 10, 2025, with the primary completion and estimated completion dates yet to be announced. The latest update was also on September 10, 2025, indicating the study is actively recruiting participants.
Market Implications: This study’s progress could significantly impact Vanda Pharmaceuticals’ stock performance, as successful results may boost investor confidence and market valuation. Given the competitive landscape in ophthalmic treatments, positive outcomes could position Vanda favorably against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.
